<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209504</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00104053</org_study_id>
    <nct_id>NCT04209504</nct_id>
  </id_info>
  <brief_title>Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block</brief_title>
  <official_title>Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective observational study aims to evaluate the incidence of hemidiaphragmatic
      paralysis in patients receiving interscalene brachial plexus nerve block with prolonged
      neural blockade. English speaking American Society of Anesthesiologists (ASA) 1-3 patients
      ages 18-80 receiving prolonged interscalene nerve block will be randomized into 2 groups, one
      group receiving a perineural catheter infusing 0.2% ropivacaine and the other group receiving
      a single shot injection of liposomal bupivacaine plus admixed plain bupivacaine. Primary
      outcome will be incidence of hemidiaphragmatic paralysis postoperative day 1 as measured by
      point of care (POCUS) ultrasound.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective observational study aims to evaluate the incidence of hemidiaphragmatic
      paralysis in patients receiving interscalene brachial plexus nerve block with prolonged
      neural blockade. English speaking ASA 1-3 patients ages 18-80 receiving prolonged
      interscalene nerve block will be randomized into 2 groups, one group receiving a perineural
      catheter infusing 0.2% ropivacaine and the other group receiving a single shot injection of
      liposomal bupivacaine plus admixed plain bupivacaine. Primary outcome will be incidence of
      hemidiaphragmatic paralysis postoperative day 1 as measured by point of care (POCUS)
      ultrasound. Secondary outcomes include incidence of hemidiaphragmatic paralysis as measured
      by point of care ultrasound (POCUS) in the immediate postoperative period, postoperative day
      (POD) 1, POD2, and POD3 and noninvasive measures of pulmonary gas exchange at pre-op,
      post-op, POD1, POD2, and POD3. Additionally, the investigators will look at pain scores
      (scale of 0-10) and opioid consumption (in oral morphine equivalents) at previously defined
      time points listed above. Furthermore, the investigators will record known side effects of
      interscalene blocks including hoarseness and Horner's syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemidiaphragmatic paralysis - ipsilateral - postoperative day (POD) 1</measure>
    <time_frame>24 hours</time_frame>
    <description>Ultrasound guided evaluation of ipsilateral hemidiaphragmatic paralysis POD1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemidiaphragmatic paralysis - ipsilateral - PACU, POD2, POD3</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Ultrasound guided evaluation of ipsilateral hemidiaphragmatic paralysis in PACU, POD2, and POD 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noninvasive pulmonary measures of gas exchange</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Noninvasive pulmonary measures of gas exchange</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Numerical Rating Scale (NRS) 11 pain scores (0-10; 0=no pain, 10=worst pain ever) at Post Anesthesia Care Unit (PACU), POD1, POD2, POD3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Opioid consumption in Oral Morphine Equivalents (OMEs) at PACU, POD1, POD2, POD3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hoarseness</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Incidence of recurrent laryngeal nerve palsy (subjective)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Horner's Syndrome</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Incidence of Horner's Syndrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Shoulder Surgery</condition>
  <condition>Shoulder Pain</condition>
  <condition>Shoulder Injuries</condition>
  <condition>Shoulder Arthritis</condition>
  <condition>Shoulder Disease</condition>
  <condition>Rotator Cuff Tears</condition>
  <condition>Rotator Cuff Injuries</condition>
  <condition>Rotator Cuff Arthropathy of Left Shoulder</condition>
  <condition>Rotator Cuff Arthropathy of Right Shoulder</condition>
  <condition>Rotator Cuff Repair</condition>
  <arm_group>
    <arm_group_label>Continuous Perineural Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placement of preoperative continuous perineural catheter using 25 millimeters (mL) 0.2% ropivacaine with 1:400,000k ropivacaine for initial block and 0.2% ropivacaine for continuous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine Single Shot</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placement of preoperative single shot using 20mL liposomal bupivacaine admixed with 5mL 0.5% bupivacaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Ultrasound guided evaluation of diaphragm ipsilateral to the block side.</description>
    <arm_group_label>Continuous Perineural Catheter</arm_group_label>
    <arm_group_label>Liposomal Bupivacaine Single Shot</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Local anesthetic (numbing drug)</description>
    <arm_group_label>Continuous Perineural Catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Local anesthetic (numbing drug)</description>
    <arm_group_label>Liposomal Bupivacaine Single Shot</arm_group_label>
    <other_name>Liposomal bupivacaine</other_name>
    <other_name>Exparel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English speaking 18-80 year old ASA 1-3 patients

          -  Primary shoulder surgery

          -  Must live within a 25 mile radius

        Exclusion Criteria:

          -  ASA 4 or 5

          -  Revision shoulder surgery

          -  Diagnosis of chronic pain

          -  Daily chronic opioid use (over 3 months of continuous opioid use)

          -  Inability to communicate pain scores or need for analgesia

          -  Infection at the site of block placement

          -  Age under 18 years old or greater than 80 years old

          -  Pregnant women (as determined by point-of-care serum bHCG)

          -  Intolerance/allergy to local anesthetics

          -  Weight &lt;50 kg

          -  BMI &gt; 40

          -  severe pulmonary disease including chronic obstructive pulmonary disease and
             restrictive lung disease

          -  Suspected, or known addiction to or abuse of illicit drug(s), prescription
             medicine(s), or alcohol within the past 2 years.

          -  Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the
             opinion of the investigator, may interfere with study assessments or compliance.

          -  Current or historical evidence of any clinically significant disease or condition
             that, in the opinion of the investigator, may increase the risk of surgery or
             complicate the subject's postoperative course.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>WIlliam M Bullock, MD, PhD</last_name>
    <phone>919-681-6437</phone>
    <email>william.bullock@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Kumar, MD</last_name>
    <phone>919-681-6437</phone>
    <email>amanda.kumar@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>William M Bullock, MD, PhD</last_name>
      <phone>919-681-6437</phone>
      <email>william.bullock@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Kumar, MD</last_name>
      <phone>919-681-6437</phone>
      <email>amanda.kumar@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amanda Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William M Bullock, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff C Gadsden, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotator Cuff Repair</keyword>
  <keyword>Shoulder Surgery</keyword>
  <keyword>Hemidiaphragmatic paralysis</keyword>
  <keyword>Interscalene Block</keyword>
  <keyword>Interscalene Catheter</keyword>
  <keyword>Interscalene Liposomal Bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Rotator Cuff Injuries</mesh_term>
    <mesh_term>Shoulder Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared; patients will be deidentified and no personal information or medical records used once patient has completed the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

